<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8796378</article-id>
    <article-id pub-id-type="pmid">34788790</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btab759</article-id>
    <article-id pub-id-type="publisher-id">btab759</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Notes</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Sequence Analysis</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>nextNEOpi: a comprehensive pipeline for computational neoantigen prediction</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Rieder</surname>
          <given-names>Dietmar</given-names>
        </name>
        <aff><institution>Biocenter, Institute of Bioinformatics, Medical University of Innsbruck</institution>, Innsbruck 6020, <country country="AT">Austria</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Fotakis</surname>
          <given-names>Georgios</given-names>
        </name>
        <aff><institution>Biocenter, Institute of Bioinformatics, Medical University of Innsbruck</institution>, Innsbruck 6020, <country country="AT">Austria</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ausserhofer</surname>
          <given-names>Markus</given-names>
        </name>
        <aff><institution>Biocenter, Institute of Bioinformatics, Medical University of Innsbruck</institution>, Innsbruck 6020, <country country="AT">Austria</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>René</surname>
          <given-names>Geyeregger</given-names>
        </name>
        <aff><institution>St. Anna Children’s Cancer Research Institute</institution>, Vienna 1090, <country country="AT">Austria</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Paster</surname>
          <given-names>Wolfgang</given-names>
        </name>
        <aff><institution>St. Anna Children’s Cancer Research Institute</institution>, Vienna 1090, <country country="AT">Austria</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Trajanoski</surname>
          <given-names>Zlatko</given-names>
        </name>
        <aff><institution>Biocenter, Institute of Bioinformatics, Medical University of Innsbruck</institution>, Innsbruck 6020, <country country="AT">Austria</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0712-4658</contrib-id>
        <name>
          <surname>Finotello</surname>
          <given-names>Francesca</given-names>
        </name>
        <xref rid="btab759-cor1" ref-type="corresp"/>
        <aff><institution>Biocenter, Institute of Bioinformatics, Medical University of Innsbruck</institution>, Innsbruck 6020, <country country="AT">Austria</country></aff>
        <aff><institution>Institute of Molecular Biology, University Innsbruck</institution>, Innsbruck 6020, <country country="AT">Austria</country></aff>
        <aff><institution>Digital Science Center (DiSC), University Innsbruck</institution>, Innsbruck 6020, <country country="AT">Austria</country></aff>
        <!--francesca.finotello@uibk.ac.at-->
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Valencia</surname>
          <given-names>Alfonso</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btab759-cor1">To whom correspondence should be addressed.</corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <day>15</day>
      <month>2</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2021-11-12">
      <day>12</day>
      <month>11</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>12</day>
      <month>11</month>
      <year>2021</year>
    </pub-date>
    <volume>38</volume>
    <issue>4</issue>
    <fpage>1131</fpage>
    <lpage>1132</lpage>
    <history>
      <date date-type="received">
        <day>16</day>
        <month>6</month>
        <year>2021</year>
      </date>
      <date date-type="rev-recd">
        <day>30</day>
        <month>9</month>
        <year>2021</year>
      </date>
      <date date-type="editorial-decision">
        <day>30</day>
        <month>10</month>
        <year>2021</year>
      </date>
      <date date-type="corrected-typeset">
        <day>19</day>
        <month>11</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2021. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2021</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btab759.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Summary</title>
        <p>Somatic mutations and gene fusions can produce immunogenic neoantigens mediating anticancer immune responses. However, their computational prediction from sequencing data requires complex computational workflows to identify tumor-specific aberrations, derive the resulting peptides, infer patients’ Human Leukocyte Antigen types and predict neoepitopes binding to them, together with a set of features underlying their immunogenicity. Here, we present nextNEOpi (<italic toggle="yes">next</italic>flow <italic toggle="yes">NEO</italic>antigen prediction <italic toggle="yes">pi</italic>peline) a comprehensive and fully automated bioinformatic pipeline to predict tumor neoantigens from raw DNA and RNA sequencing data. In addition, nextNEOpi quantifies neoepitope- and patient-specific features associated with tumor immunogenicity and response to immunotherapy.</p>
      </sec>
      <sec id="s2">
        <title>Availability and implementation</title>
        <p>nextNEOpi source code and documentation are available at <ext-link xlink:href="https://github.com/icbi-lab/nextNEOpi" ext-link-type="uri">https://github.com/icbi-lab/nextNEOpi</ext-link></p>
      </sec>
      <sec id="s3">
        <title>Contact</title>
        <p><email>dietmar.rieder@i-med.ac.at</email> or <email>francesca.finotello@uibk.ac.at</email></p>
      </sec>
      <sec id="s4">
        <title>Supplementary information</title>
        <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Austrian Science Fund (FWF)</institution>
          </institution-wrap>
        </funding-source>
        <award-id>T 974-B30</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Oesterreichische Nationalbank (OeNB)</institution>
          </institution-wrap>
        </funding-source>
        <award-id>18496</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>European Research Council (ERC)</institution>
          </institution-wrap>
        </funding-source>
        <award-id>786295</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="2"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>T-cell mediated recognition of tumor neoantigens is pivotal for the success of anticancer immunotherapies (<xref rid="btab759-B10" ref-type="bibr">Schumacher <italic toggle="yes">et al.</italic>, 2019</xref>). Thus, <italic toggle="yes">in silico</italic> prediction of patient-specific neoepitopes from whole-exome (WES), whole-genome (WGS), and RNA sequencing (RNA-seq) data is a fundamental task in immuno-oncology. To this end, complex computational pipelines must be assembled to predict tumor-specific, mutated peptides and their likelihood of binding the patients’ Human Leukocyte Antigen (HLA) molecules and being recognized by T cells (<xref rid="btab759-B3" ref-type="bibr">Finotello <italic toggle="yes">et al.</italic>, 2019</xref>; <xref rid="btab759-B12" ref-type="bibr">Wells <italic toggle="yes">et al.</italic>, 2020</xref>). In addition to neoantigens derived from single-nucleotide variants (SNVs) and insertions or deletions (indels), gene fusions can be a source of <italic toggle="yes">noncanonical</italic> neoantigens (<xref rid="btab759-B13" ref-type="bibr">Yang <italic toggle="yes">et al.</italic>, 2019</xref>).</p>
    <p>In recent years, several pipelines for the prediction of neoantigens have been developed (see recent review, <xref rid="btab759-B3" ref-type="bibr">Finotello <italic toggle="yes">et al.</italic>, 2019</xref>), but most of them require cumbersome software installation and extensive data preprocessing with third-party tools to predict somatic mutations and HLA types. Moreover, to the best of our knowledge, most of the available pipelines are not able to predict class-II and noncanonical neoantigens, or to extract features associated to anticancer immune responses like mutation clonality and immune-cell receptor repertoires (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>). Here, we present nextNEOpi (<italic toggle="yes">next</italic>flow <italic toggle="yes">NEO</italic>antigen prediction <italic toggle="yes">pi</italic>peline), a fully automated and comprehensive computational workflow that overcomes these shortcomings. nextNEOpi predicts class-I and -II neoantigens originating from SNVs, indels and gene fusions through the analysis of raw sequencing data and derives a set of features associated with tumor immunogenicity and response to immunotherapy.</p>
  </sec>
  <sec>
    <title>2 The nextNEOpi pipeline</title>
    <p>nextNEOpi takes as input raw WES or WGS data from matched tumor-normal samples and, optionally, bulk-tumor RNA-seq data (<xref rid="btab759-F1" ref-type="fig">Fig.  1</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1</xref>). After data preprocessing, nextNEOpi derives germline and phased somatic mutations, copy number variants, tumor purity and ploidy, and selects high-confidence variants through majority voting (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>).</p>
    <fig position="float" id="btab759-F1">
      <label>Fig. 1.</label>
      <caption>
        <p>Schematization of nextNEOpi pipeline with main input data (white boxes), data flow (lines), intermediate (grey boxes) and final (grey boxes with borders) outputs. </p>
      </caption>
      <graphic xlink:href="btab759f1" position="float"/>
    </fig>
    <p>nextNEOpi infers class-I and -II HLA types from WES/WGS (DNA-seq) and RNA-seq data using OptiType (<xref rid="btab759-B11" ref-type="bibr">Szolek <italic toggle="yes">et al.</italic>, 2014</xref>) and HLA-HD (<xref rid="btab759-B7" ref-type="bibr">Kawaguchi <italic toggle="yes">et al.</italic>, 2017</xref>), respectively, and can employ an RNA-seq-informed strategy to correct DNA-seq calls for missing HLA genes or alleles (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>). HLA typing benchmarking using data from the 1000 Genomes Project confirmed the high performance of OptiType and HLA-HD, especially on RNA-seq data (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figs S2–S4</xref>). DNA-seq calls showed a lower accuracy, a systematic underestimation of zygosity and a higher number of missing calls likely due to the low sequencing depth of WGS data (∼4–29 million reads per sample), which were improved using the RNA-seq-informed approach.</p>
    <p>nextNEOpi uses pVACseq (<xref rid="btab759-B5" ref-type="bibr">Hundal <italic toggle="yes">et al.</italic>, 2020</xref>) to predict class-I and -II neoepitopes and derive features associated with neoantigen presentation, including peptide-HLA-binding affinity quantified as half-maximal inhibitory concentration (IC<sub>50</sub>) and percentile rank quantified by NetMHCpan (<xref rid="btab759-B6" ref-type="bibr">Jurtz <italic toggle="yes">et al.</italic>, 2017</xref>) and MHCflurry (<xref rid="btab759-B9" ref-type="bibr">O’Donnell <italic toggle="yes">et al.</italic>, 2020</xref>). Class-I and -II fusion neoepitopes are predicted with NeoFuse (<xref rid="btab759-B4" ref-type="bibr">Fotakis <italic toggle="yes">et al.</italic>, 2020</xref>). </p>
    <p>nextNEOpi exploits tumor purity information to derive the cancer cell fraction (CCF) and clonality of mutations and resulting neoantigens. Tumor mutational burden (TMB) is computed as the number of somatic mutations over the entire read-covered genome or exome. In addition, <italic toggle="yes">clonal</italic> TMB is computed by considering only clonal somatic mutations (<xref rid="btab759-B8" ref-type="bibr">Litchfield <italic toggle="yes">et al.</italic>, 2021</xref>). MiXCR is used to predict B-cell receptor and T-cell receptor (BCR and TCR) repertoires (<xref rid="btab759-B1" ref-type="bibr">Bolotin <italic toggle="yes">et al.</italic>, 2015</xref>). An overview of nextNEOpi results is provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Tables S2–S4</xref>.</p>
    <p>We implemented nextNEOpi in the Nextflow workflow language (<xref rid="btab759-B2" ref-type="bibr">Di Tommaso <italic toggle="yes">et al.</italic>, 2017</xref>) to assure portability, scalability, and reproducibility. Parallelization is implicitly defined by inputs and outputs of the individual pipeline tasks, enabling transparent scale-up without requiring adaptation to a specific platform architecture. By leveraging conda environment and singularity container capabilities, the installation demands for nextNEOpi are kept on a minimal level facilitating its usage by users with limited bioinformatics expertise.</p>
  </sec>
  <sec>
    <title>3 Analysis of TESLA data with nextNEOpi</title>
    <p>To benchmark nextNEOpi, we considered WES and RNA-seq data from two cohorts of melanoma and non-small cell lung cancer patients (<italic toggle="yes">n</italic> = 8) generated by the Tumor Neoantigen Selection Alliance (TESLA) initiative (<xref rid="btab759-B12" ref-type="bibr">Wells <italic toggle="yes">et al.</italic>, 2020</xref>). nextNEOpi predicted 30 912–364 532 putative HLA-binding peptides (pMHC) per patient, spanning 5152–90 819 unique peptides (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S5</xref>). The identified pMHC represented 76.40–92.59% of those assessed by TESLA and covered 75.00–100% of the total immunogenic pMHC. In total, 36 over 38 immunogenic pMHC were identified. Prioritization of candidate neoepitopes based on <italic toggle="yes">relaxed</italic> filtering (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>) resulted in the identification of 32 over 38 immunogenic pMHC (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S6</xref>).</p>
    <p>We considered all pMHC experimentally assessed by TESLA to investigate the features associated with immunogenicity. All scores related to HLA-binding affinity of the mutated peptides were strongly associated with immunogenicity (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S5</xref>): immunogenic peptides showed a lower IC<sub>50</sub> (<italic toggle="yes">P</italic> = 5.8e−11) and percentile rank (<italic toggle="yes">P</italic> = 1.6e−10). The IC<sub>50</sub> fold-change was not discriminative (<italic toggle="yes">P</italic> = 0.45), whereas the expression of the mutated gene was higher for immunogenic peptides (<italic toggle="yes">P</italic> = 9.9e−5). Clonality features showed different distributions for immunogenic and non-immunogenic peptides, with the former having higher CCF 5% confidence interval (<italic toggle="yes">P</italic> = 0.017) and probability of being clonal (<italic toggle="yes">P</italic> = 0.024). Clonal neoantigens were enriched in patients responding to immune checkpoint blockers, whereas subclonal mutations were associated with a single patient (Pat_8) with progressive disease (PD).</p>
    <p>The investigation of TMB and diversity of immune receptor repertoires can provide further insights into the antigenicity of the tumors and immune-cell infiltration and expansion in the single patients (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S6</xref>).</p>
  </sec>
  <sec>
    <title>4 Conclusions</title>
    <p>nextNEOpi is a comprehensive and fully automated pipeline that predicts tumor neoepitopes from raw sequencing data. It is implemented in Nextflow to ensure easy installation and usage, as well as high portability, scalability (see example computational times in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S7</xref>), and reproducibility. nextNEOpi quantifies neoepitope- and patient-specific features associated with tumor immunogenicity and response to immunotherapy, and uses multi-method consensus approaches to guarantee robust results in case of suboptimal data. In the near future, we plan to extend nextNEOpi to other classes of noncanonical neoantigens and to introduce DSL 2 Nextflow syntax to facilitate the integration of additional features relevant for neoantigen prioritization.</p>
  </sec>
  <sec sec-type="data-availability">
    <title>Data availability</title>
    <p>References and accession numbers to the published data analyzed in this work are reported in the <xref rid="sup1" ref-type="supplementary-material">Supplementary Material</xref>.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>This work was supported by the Austrian Science Fund (FWF) [T 974-B30 to F.F.], by the Oesterreichische Nationalbank (OeNB) [18496 to F.F.] and by the European Research Council (ERC) [786295 to Z.T.]. </p>
    <p><italic toggle="yes">Conflict of Interest</italic>: none declared.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btab759_supplementary_data</label>
      <media xlink:href="btab759_supplementary_data.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btab759-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bolotin</surname><given-names>D.A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2015</year>) <article-title>MiXCR: software for comprehensive adaptive immunity profiling</article-title>. <source>Nat. Methods</source>, <volume>12</volume>, <fpage>380</fpage>–<lpage>381</lpage>.<pub-id pub-id-type="pmid">25924071</pub-id></mixed-citation>
    </ref>
    <ref id="btab759-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Di Tommaso</surname><given-names>P.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2017</year>) <article-title>Nextflow enables reproducible computational workflows</article-title>. <source>Nat. Biotechnol</source>., <volume>35</volume>, <fpage>316</fpage>–<lpage>319</lpage>.<pub-id pub-id-type="pmid">28398311</pub-id></mixed-citation>
    </ref>
    <ref id="btab759-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Finotello</surname><given-names>F.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2019</year>) <article-title>Next-generation computational tools for interrogating cancer immunity</article-title>. <source>Nat. Rev. Genet</source>., <volume>20</volume>, <fpage>724</fpage>–<lpage>746</lpage>.<pub-id pub-id-type="pmid">31515541</pub-id></mixed-citation>
    </ref>
    <ref id="btab759-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fotakis</surname><given-names>G.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2020</year>) <article-title>NeoFuse: predicting fusion neoantigens from RNA sequencing data</article-title>. <source>Bioinformatics</source>, <volume>36</volume>, <fpage>2260</fpage>–<lpage>2261</lpage>.<pub-id pub-id-type="pmid">31755900</pub-id></mixed-citation>
    </ref>
    <ref id="btab759-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hundal</surname><given-names>J.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2020</year>) <article-title>pVACtools: a computational toolkit to identify and visualize cancer neoantigens</article-title>. <source>Cancer Immunol Res</source>., <volume>8</volume>, <fpage>409</fpage>–<lpage>420</lpage>.<pub-id pub-id-type="pmid">31907209</pub-id></mixed-citation>
    </ref>
    <ref id="btab759-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jurtz</surname><given-names>V.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2017</year>) <article-title>NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data</article-title>. <source>J. Immunol</source>., <volume>199</volume>, <fpage>3360</fpage>–<lpage>3368</lpage>.<pub-id pub-id-type="pmid">28978689</pub-id></mixed-citation>
    </ref>
    <ref id="btab759-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kawaguchi</surname><given-names>S.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2017</year>) <article-title>HLA-HD: an accurate HLA typing algorithm for next-generation sequencing data</article-title>. <source>Hum. Mutat</source>., <volume>38</volume>, <fpage>788</fpage>–<lpage>797</lpage>.<pub-id pub-id-type="pmid">28419628</pub-id></mixed-citation>
    </ref>
    <ref id="btab759-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Litchfield</surname><given-names>K.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2021</year>) <article-title>Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition</article-title>. <source>Cell</source>, <volume>184</volume>, <fpage>596</fpage>–<lpage>614.e14</lpage>.<pub-id pub-id-type="pmid">33508232</pub-id></mixed-citation>
    </ref>
    <ref id="btab759-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Donnell</surname><given-names>T.J.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2020</year>) <article-title>MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing</article-title>. <source>Cell Syst</source>., <volume>11</volume>, <fpage>42</fpage>–<lpage>48.e7</lpage>.<pub-id pub-id-type="pmid">32711842</pub-id></mixed-citation>
    </ref>
    <ref id="btab759-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schumacher</surname><given-names>T.N.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2019</year>) <article-title>Cancer neoantigens</article-title>. <source>Annu. Rev. Immunol</source>., <volume>37</volume>, <fpage>173</fpage>–<lpage>200</lpage>.<pub-id pub-id-type="pmid">30550719</pub-id></mixed-citation>
    </ref>
    <ref id="btab759-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szolek</surname><given-names>A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2014</year>) <article-title>OptiType: precision HLA typing from next-generation sequencing data</article-title>. <source>Bioinformatics</source>, <volume>30</volume>, <fpage>3310</fpage>–<lpage>3316</lpage>.<pub-id pub-id-type="pmid">25143287</pub-id></mixed-citation>
    </ref>
    <ref id="btab759-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wells</surname><given-names>D.K.</given-names></string-name></person-group>  <etal>et al</etal>; Tumor Neoantigen Selection Alliance. (<year>2020</year>) <article-title>Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction</article-title>. <source>Cell</source>, <volume>183</volume>, <fpage>818</fpage>–<lpage>834.e13</lpage>.<pub-id pub-id-type="pmid">33038342</pub-id></mixed-citation>
    </ref>
    <ref id="btab759-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>W.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2019</year>) <article-title>Immunogenic neoantigens derived from gene fusions stimulate T cell responses</article-title>. <source>Nat. Med</source>., <volume>25</volume>, <fpage>767</fpage>–<lpage>775</lpage>.<pub-id pub-id-type="pmid">31011208</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
